OncoCyte Investor Relations Material
Latest events
Q3 2024
OncoCyte
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from OncoCyte Corporation
Access all reports
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. Its tests apply genetic analysis technology to advance early detection of cancer. The company's lead product candidates are Circulating Tumor Cell (CTC), a blood test to detect lung cancer; and DetermaIO, a bioinformatic analysis software that provides interpretative information on the outputs from various types of assays, including CTC. It is also developing DetermaVu, a cell free DNA blood test for detecting various types of lung cancer; DetermaSolver, a proprietary technology.
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
OCX
Country
πΊπΈ United States